EGFR and cancer: At the same time, EGFR-TKI can compete with adenosine triphosphate for tyrosine kinase sites, thereby inhibiting intracellular tyrosine kinase phosphorylation, epidermal growth factor receptor signaling, and cancer cell proliferation, growth, and angiogenesis, thus playing an anti-tumor role in progressive and recurrent NSCLC (31).